UPDATE 4-Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion
Amgen Inc will buy Celgene
Corp’s psoriasis drug Otezla for $13.4 billion in cash,
clearing the way for Bristol-Myers Squibb to go ahead
with its $74 billion deal for Celgene by the end of the year.